CCBL1 Antibody

What is CCBL1/KAT1 and why is it important in research?

CCBL1 (also known as KAT1 or KYAT1) encodes kynurenine aminotransferase 1, a key enzyme involved in the kynurenine pathway. It catalyzes the production of kynurenic acid, a powerful endogenous excitatory amino acid receptor antagonist widely regarded as a potent neuroprotective agent . CCBL1 also metabolizes cysteine conjugates of certain halogenated alkenes and alkanes to form reactive metabolites and catalyzes beta-elimination of S-conjugates and Se-conjugates of L-(seleno)cysteine . Its involvement in tryptophan metabolism and neuroprotective mechanisms makes it an important target for neuroscience, immunology, and metabolic research.

How do I select the appropriate CCBL1 antibody for my research needs?

Selection should be based on:

• Application compatibility: Determine if the antibody is validated for your intended application (WB, IHC, IF/ICC, ELISA)

• Species reactivity: Confirm reactivity with your target species (human, mouse, rat, etc.)

• Antibody characteristics: Consider format (polyclonal vs. monoclonal), host species, and isotype

• Epitope recognition: For specific domain targeting, review the immunogen information

• Validation data: Examine published validation data for the specific applications you require

For example, if conducting Western blot with human samples, look for antibodies validated specifically for human CCBL1 in WB applications with demonstrated specificity at the expected molecular weight (48-50 kDa) .

What are the optimal dilutions for CCBL1 antibodies in different applications?

Optimal dilutions vary by application and specific antibody:

Always titrate the antibody in your specific experimental system for optimal results, as the ideal dilution may vary based on tissue type, fixation method, and detection system .

How should I prepare samples for Western blot detection of CCBL1?

For optimal CCBL1 detection by Western blot:

• Lysate preparation:

  • Effectively validated in HeLa cells, L02 cells, and mouse kidney tissue

  • Use RIPA or NP-40 buffer with protease inhibitors

  • Load 25-30 μg protein per lane

• Gel conditions:

  • Use 10-12% SDS-PAGE for optimal separation around 48-50 kDa

• Transfer and blocking:

  • Transfer to PVDF membrane (validated in published protocols)

  • Block with 5% w/v milk in TBS with 0.1% Tween-20

• Detection recommendations:

  • Primary antibody incubation: overnight at 4°C with gentle shaking

  • Appropriate HRP-conjugated secondary antibody based on host species

  • ECL detection with 90-second exposure as starting point

What controls should I include when using CCBL1 antibodies?

Implementing appropriate controls ensures reliable results:

• Positive controls: Use tissues/cells with known CCBL1 expression

  • Mouse kidney tissue, HeLa cells, and L02 cells are validated positive controls

  • HepG2, rat kidney tissue also show detectable expression

• Negative controls:

  • Primary antibody omission

  • Non-specific IgG matching the host species of the primary antibody

  • Peptide competition assay using the immunizing peptide when available

• Loading controls: Include housekeeping proteins (β-actin, GAPDH) to normalize expression levels

• Validation through multiple techniques: Confirm findings using orthogonal methods (e.g., qPCR for mRNA expression)

How can I reduce background when using CCBL1 antibodies in immunohistochemistry?

To minimize background in IHC applications:

• Optimize blocking:

  • Use 5-10% normal serum from the same species as the secondary antibody

  • Consider adding 0.1-0.3% Triton X-100 for better penetration

• Antibody dilution optimization:

  • Start with the recommended range (1:50-1:200) and titrate as needed

  • Increased dilution may reduce background while maintaining specific signal

• Antigen retrieval modifications:

  • Heat-mediated antigen retrieval in citrate buffer has been validated

  • Optimize retrieval time and temperature for your specific tissue

• Incubation conditions:

  • For paraffin sections, 1.5 hours at 22°C has shown good results

  • Consider overnight incubation at 4°C for stronger specific signals with less background

• Detection system selection:

  • HRP-conjugated secondary antibodies with appropriate dilution

  • Consider polymer-based detection systems for enhanced sensitivity and reduced background

Why might I observe multiple bands when performing Western blot for CCBL1?

Multiple bands in CCBL1 Western blots may occur due to:

• Isoform detection: CCBL1/KAT1 has multiple reported isoforms

• Post-translational modifications: Phosphorylation, glycosylation, or other modifications can alter migration patterns

• Degradation products: Improper sample handling or storage may cause protein degradation

• Cross-reactivity: Antibody may recognize related proteins, especially in polyclonal preparations

• Expected molecular weight variation: The observed molecular weight (48-50 kDa) can vary slightly from the calculated weight (48 kDa)

Verification approaches:

• Compare results with multiple CCBL1 antibodies targeting different epitopes

• Conduct peptide competition assays

• Validate with recombinant protein standards

• Consider species-specific variations in protein size and modifications

How can CCBL1 antibodies be used to investigate the kynurenine pathway in neurological disorders?

CCBL1/KAT1 plays a crucial role in synthesizing kynurenic acid, a neuroprotective agent . Researchers can:

• Employ tissue-specific analyses:

  • Use immunohistochemistry to map KAT1 distribution in brain regions affected by neurological disorders

  • Compare expression levels between control and disease tissues using quantitative Western blot analysis

• Develop co-localization studies:

  • Combine CCBL1 antibodies with markers for specific cell types (neurons, microglia, astrocytes)

  • Use IF/ICC applications with 1:50-1:500 dilutions

• Implement functional assays:

  • Correlate protein expression with enzymatic activity measurements

  • Combine with metabolite analysis (kynurenic acid levels) using MS/HPLC techniques

• Utilize animal models:

  • Given the antibodies' reactivity with mouse and rat samples , investigate KAT1 expression changes in rodent models of neurological disorders

  • Combine with behavioral assessments to correlate biochemical changes with functional outcomes

What considerations are important when using CCBL1 antibodies for multiplex immunofluorescence?

For successful multiplex staining:

• Antibody compatibility assessment:

  • Select CCBL1 antibodies from different host species than other target antibodies

  • For rabbit-derived CCBL1 antibodies , pair with mouse, goat, or rat antibodies for other targets

• Fluorophore selection:

  • Choose fluorophores with minimal spectral overlap

  • Consider signal strength (CCBL1 may require brighter fluorophores if expression is low)

• Sequential staining optimization:

  • Determine optimal staining sequence (often starting with lower-expressing targets)

  • Include appropriate blocking steps between antibody applications

• Cross-reactivity control:

  • Test each antibody individually before multiplexing

  • Include controls with single primary antibodies to confirm specificity

• Dilution re-optimization:

  • Antibody dilutions validated for single staining may need adjustment in multiplex protocols

  • For CCBL1, start with the recommended IF/ICC range (1:50-1:500) and adjust as needed

How can CCBL1 antibodies be used to study developability profiles for therapeutic antibodies?

CCBL1 antibodies can serve as model systems for studying therapeutic antibody developability:

• Biophysical property assessment:

  • Analyze thermostability, aggregation propensity, and colloidal stability of different CCBL1 antibody formats

  • Apply techniques used in antibody engineering to optimize CCBL1 antibody performance

• Comparative analysis across formats:

  • Compare polyclonal versus monoclonal CCBL1 antibodies for specificity and sensitivity

  • Assess how different host species and isotypes impact performance metrics

• Sequence engineering studies:

  • Utilize the diverse epitope recognition across available CCBL1 antibodies to study structure-function relationships

  • Apply insights from antibody engineering research to improve specificity and affinity

• High-throughput screening applications:

  • Implement assays that evaluate parameters like thermal stability and aggregation propensity

  • Correlate biophysical properties with functional outcomes in research applications

This approach leverages the documented diversity in CCBL1 antibodies to provide insights applicable to therapeutic antibody development while maintaining focus on research applications.

How can computational modeling enhance CCBL1 antibody specificity and application?

Recent advances in computational antibody engineering can be applied to CCBL1 research:

• Epitope-specific binding profile analysis:

  • Use computational methods to predict binding modes for different CCBL1 antibodies

  • Apply machine learning approaches to identify sequence features that enhance specificity

• Cross-reactivity prediction:

  • Leverage sequence analysis to predict potential cross-reactivity with related proteins

  • Design validation experiments to confirm computational predictions

• Customized specificity profiles:

  • Apply computational design principles to generate antibodies with enhanced specificity for specific CCBL1 epitopes

  • Use phage display data to train models for predicting antibody-antigen interactions

• Structure-guided optimization:

  • Utilize structural bioinformatics to identify critical binding residues

  • Design modifications that could enhance binding to specific domains of CCBL1

Implementation of these approaches can lead to more targeted and specific CCBL1 antibodies for specialized research applications, following models that have been successful with other antibody targets .

What are the considerations for using CCBL1 antibodies in single-cell analysis techniques?

For effective single-cell analysis:

• Antibody sensitivity optimization:

  • Higher antibody concentrations may be needed for detecting low abundance proteins in single cells

  • Start with the upper end of the recommended concentration range for IF/ICC (1:50)

• Background minimization strategies:

  • Implement rigorous blocking protocols to reduce non-specific binding

  • Consider signal amplification systems for low-expressing cells

• Validation in relevant cell types:

  • Test in cell types with known CCBL1 expression (HeLa cells have been validated)

  • Include positive and negative control cells in single-cell experimental designs

• Compatibility with fixation and permeabilization protocols:

  • Optimize fixation conditions (4% paraformaldehyde is standard)

  • Test different permeabilization reagents (0.1-0.3% Triton X-100, 0.1% saponin)

• Multiplexing considerations:

  • Evaluate potential antibody cross-talk in multiplexed applications

  • Select compatible secondary detection systems that minimize spectral overlap

These considerations help ensure accurate detection of CCBL1 in heterogeneous cell populations for single-cell research applications.